~~<i id='DB2AFA2345'><strike id='DB2AFA2345'><tt id='DB2AFA2345'><pre id='DB2AFA2345'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：fashion 2025-10-02 18:16:08 Page View：8434

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： I was wrong about Geron's blood cancer drug. Now, is it a takeover target?
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Neuroscience’s long legacy of racism

AdobeManypartsofneuroscienceresearchhavearaceproblem.Blackpeopleareoftenexcludedfromstudiesduetothet

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Stop the failed accountable care organization experiment

AdobeForthelasthalf-century,Congresshasendorsedessentiallythesameapproachtocuttinghealthcarecosts,an